S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:INKT

MiNK Therapeutics (INKT) Stock Price, News & Analysis

$0.88
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
$0.86
$0.90
50-Day Range
$0.86
$1.56
52-Week Range
$0.75
$3.34
Volume
40,426 shs
Average Volume
191,504 shs
Market Capitalization
$30.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

MiNK Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
927.0% Upside
$9.00 Price Target
Short Interest
Healthy
0.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.59) to ($0.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.13 out of 5 stars

Medical Sector

320th out of 907 stocks

Biotechnology Industry

4th out of 18 stocks

INKT stock logo

About MiNK Therapeutics Stock (NASDAQ:INKT)

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

INKT Stock Price History

INKT Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
MiNK Reports Fourth Quarter and Year-End 2023 Results
Earnings Outlook For MiNK Therapeutics
MiNK Therapeutics Inc INKT
MiNK Therapeutics GAAP EPS of -$0.15
MiNK Therapeutics Reports Third Quarter 2023 Results
MiNK Therapeutics Insider Ups Holding During Year
See More Headlines
Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/21/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:INKT
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+927.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-22,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.52) per share

Miscellaneous

Free Float
28,519,000
Market Cap
$30.41 million
Optionable
No Data
Beta
0.13
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

INKT Stock Analysis - Frequently Asked Questions

Should I buy or sell MiNK Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INKT shares.
View INKT analyst ratings
or view top-rated stocks.

What is MiNK Therapeutics' stock price target for 2024?

2 analysts have issued 12 month price targets for MiNK Therapeutics' stock. Their INKT share price targets range from $9.00 to $9.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 927.0% from the stock's current price.
View analysts price targets for INKT
or view top-rated stocks among Wall Street analysts.

How have INKT shares performed in 2024?

MiNK Therapeutics' stock was trading at $1.07 on January 1st, 2024. Since then, INKT stock has decreased by 18.1% and is now trading at $0.8763.
View the best growth stocks for 2024 here
.

Are investors shorting MiNK Therapeutics?

MiNK Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 41,100 shares, a decline of 11.6% from the March 15th total of 46,500 shares. Based on an average daily volume of 99,400 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.4% of the shares of the stock are short sold.
View MiNK Therapeutics' Short Interest
.

When is MiNK Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our INKT earnings forecast
.

How were MiNK Therapeutics' earnings last quarter?

MiNK Therapeutics, Inc. (NASDAQ:INKT) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01.

When did MiNK Therapeutics IPO?

MiNK Therapeutics (INKT) raised $43 million in an IPO on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share.

How do I buy shares of MiNK Therapeutics?

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INKT) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners